AIM ImmunoTech (NYSE: AIM) to end Maxim at-the-market stock program
Rhea-AI Filing Summary
AIM ImmunoTech Inc. is terminating its Equity Distribution Agreement with Maxim Group LLC, which allowed sales of common stock in an at the market offering under Rule 415. Notice of mutual termination was given on July 31, 2026, and the termination is effective August 15, 2026. The company will not incur any termination penalties.
Under this program, from April 1, 2025 to July 31, 2026, AIM ImmunoTech sold 3,200,736 shares of common stock for aggregate gross proceeds of approximately $2.8 million. The company does not intend to issue or sell any additional shares under the Agreement before termination, and after termination it may not offer or sell any additional shares under that Agreement or the related prospectus and prospectus supplement.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
Shares sold under Equity Distribution Agreement: 3,200,736 shares
Aggregate gross proceeds: $2.8 million
Termination effective date: August 15, 2026
3 metrics
Shares sold under Equity Distribution Agreement
3,200,736 shares
Common stock sold from April 1, 2025 to July 31, 2026 under the Maxim agreement
Aggregate gross proceeds
$2.8 million
Gross proceeds from shares sold under the Equity Distribution Agreement
Termination effective date
August 15, 2026
Effective date of mutual termination of the Equity Distribution Agreement with Maxim Group LLC
Key Terms
Equity Distribution Agreement, at the market offering, Rule 415, prospectus supplement
4 terms
Equity Distribution Agreement financial
"AIM ImmunoTech Inc. is a party to the Equity Distribution Agreement"
An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.
at the market offering financial
"sell shares of common stock in sales deemed to be an “at the market offering”"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Rule 415 regulatory
"as defined in Rule 415 promulgated under the Securities Act of 1933"
Rule 415 is a U.S. Securities and Exchange Commission regulation that lets a company register securities ahead of time and then offer them for sale in pieces over an extended period under a “shelf” registration, so offerings can be launched quickly when market conditions suit the issuer. For investors, it signals that management has a ready way to raise capital fast—useful for seizing opportunities but potentially dilutive to existing shareholders, like a company pre-loading a credit line it can tap as needed.
prospectus supplement regulatory
"under the Agreement or the related prospectus and prospectus supplement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What agreement did AIM (AIM) terminate on July 31, 2026?
AIM ImmunoTech Inc. terminated its Equity Distribution Agreement with Maxim Group LLC, which had allowed sales of common stock through an at the market offering under Rule 415 of the Securities Act.
When does AIM (AIM)'s termination of the Maxim Equity Distribution Agreement become effective?
The termination of AIM ImmunoTech's Equity Distribution Agreement with Maxim Group LLC becomes effective on August 15, 2026, following notice of mutual termination provided on July 31, 2026.
Will AIM (AIM) pay any penalties for ending the Equity Distribution Agreement?
No. AIM ImmunoTech states it will not incur any termination penalties as a result of mutually terminating the Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026.
Can AIM (AIM) continue selling stock under the Maxim Equity Distribution Agreement?
After August 15, 2026, AIM ImmunoTech may not offer or sell any additional shares of common stock under the Equity Distribution Agreement or the related prospectus and prospectus supplement.